

# Ryah Medtech Inc

14:13 12 Sep 2019

## Ryah Medtech CEO Wagner says vaping's place is best reserved for the medicine cabinet

Ryah Medtech Inc CEO Greg Wagner wants people to know that there's more to vaping than the flavored e-cigarettes that are proving increasingly dangerous to young Americans.

In a post published Thursday titled "Vaping Has A Place In Society, In Your Medicine Cabinet," Wagner addressed the ongoing vaping crisis and the role of regulation in the sector.

This comes less than a week after the CDC issued a warning about e-cigarettes and vaping products. As many as 450 people, including six who have died, have been affected by a vaping-related respiratory illness, according to a report from Vox.

On Wednesday, President Trump announced a plan to ban flavored e-cigarettes outright in a move to curb teenage vaping that could have a major impact on the industry.

### READ: RYAH takes major step towards completion of its reverse takeover of Prime Blockchain

In the statement, Wagner discussed the role of vaping in medical science and argued that the issues don't fall at the feet of the technology itself.

"Vaping has been used for hundreds of years as a delivery system for medicine; access to this technology needs to remain available," Wagner said. "It's important to distinguish the ongoing benefits of dose-measuring devices and proprietary cartridges designed for precise, patient use and effective treatment versus the inferior counterfeit and black-market products out there."

The Ryah dry herb vaporizer solves those problems, Wagner said, by allowing patients to precisely regulate dosage and temperature for each vaping session and work with their doctors to find what works best.

The company also reached out to First Lady Melania Trump, who called e-cigarettes an "on-ramp to nicotine addiction" in a Tweet on Monday.

I am deeply concerned about the growing epidemic of e-cigarette use in our children. We need to do all we can to protect the public from tobacco-related disease and death, and prevent e-cigarettes from becoming an on-ramp to nicotine addiction for a generation of youth. @HHSgov

— Melania Trump (@FLOTUS) September 9, 2019

"We are encouraged to see so many public leaders tackling this health crisis, including the First Lady Melania Trump," Wagner said. "Ryah would be happy to sit down with her to discuss the data that we have been collecting for years on vaping consumption."

Wagner added: "It is a critical time to examine ongoing research and insights that will support patients and allow health care providers with access to data necessary to develop regulated, medicines for vaping and protect the public."

### Share Information

**Code:** RYAH  
**Listing:** PRIVATE-NA  
**Sector:** Cannabis  
**Website:** us.ryah.com

### Company Synopsis:

*RYAH is the first vaporizer that lets users track and control how much they inhale, ensuring consistent, predictable results. It offers accurate temperature and dosing control down to the millileter. &nbsp;*

*The device tracks the effects of each session and uses artificial intelligence to help select the best strain of cannabis for any patient's symptoms. &nbsp;*

action@proactiveinvestors.com

The Ryah vaporizer is capable of storing results from vaping sessions to create a picture for doctors and patients of how vaping is working for them and what tweaks — such as cannabis strain, dosage level, frequency or temperature — may need to be made.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter [@andrew\\_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).